News for XPHYF Stock

BioNxt Reports Update on Commercialization of Rotigotine Patch for Treatment of Parkinson's Disease BioNxt Solutions Signs Term Sheet for Novel Precision Drug Coating Platform Technology BioNxt Solutions Announces Closing of Fully Subscribed Private Placement of Convertible Debentures BioNxt Solutions Upsizes Debenture Financing to $2.808 Million BioNxt Solutions Announces Debenture Financing XPhyto Announces Name Change to BioNxt Solutions Inc. XPhyto Reports Excellent Rotigotine In-Vitro/Ex-Vivo Results for Parkinson's Disease Treatment XPhyto Completes Rotigotine Transdermal Patch Optimization and Comparative Skin Absorption Study XPhyto Signs Letter of Intent for US Manufacturing and Strategic Business Opportunities XPhyto Files Patent Application for Library of Novel Psychedelic Compounds XPhyto Closes Final Tranche of Fully Subscribed Financing XPhyto Closes Second Tranche of Financing XPhyto Pursues Potential Application of its Oral Dissolvable Biosensor Inflammation Test for Buprenorphine-related Dental Disease XPhyto Pursues Potential Application of its Oral Dissolvable Biosensor Inflammation Test for Buprenorphine-related Dental Disease XPhyto Adds Pharmaceutical Manufacturing Expert Dr. Florian A. Sahr to Its European Team XPhyto Reports Product Developments on Platform-Based Rotigotine Transdermal Patch for Parkinson’s Disease XPhyto, Biosensors Market and Product Developments on Platform-Based Oral Dissolvable Biosensors for Oral Health and Infectious Disease XPhyto Reports Market and Product Developments on Platform-based Rotigotine Transdermal Patch for Parkinson's Disease XPhyto Closes First Tranche of Financing XPhyto Provides Progress Update on Psychedelic Medicine Programs and Novel Compounds Milestone XPhyto Reports on its Three Primary Business Divisions XPhyto Executes Covid-ID Lab Sales Contracts with Test Clinics and Pharmacies in Germany as Part of Multi-Product Rollout Strategy XPhyto Provides Update on Integration of 3a-diagnostics GmbH XPhyto Announces Head of Sales, Europe XPhyto Announces New Director of Business Development and Head of Diagnostic Research XPhyto Epilepsy Clinical Trial Planned in 2022 with Its Proprietary Fast-Dissolving CBD Oral Strips XPhyto Completes Strategic Acquisition of 3a-diagnostics GmbH XPhyto Therapeutics Announces Stock Option Grants XPhyto Therapeutics Closes Private Placements for Gross Proceeds of $7,000,0000 XPhyto Announces CFO Appointment XPhyto Announces Managing Director Appointment, Financing and 3a-diagnostics Development XPhyto Reports Development Update for its Drug Delivery Business Xphyto Announces Engagement of Consultants for Marketing and Promotional Activities XPhyto Reports Successful Market Launch and Growing Demand for its 25-minute COVID-19 PCR Test COVID-ID Lab XPhyto Launches First Commercial Biosensor for Oral Disease XPhyto’s Acquisition Target, 3a-Diagnostics, Reports Breakthrough Identification of COVID-19 Biosensor Candidates XPhyto Signs Transformative Acquisition Agreement With 3a-Diagnostics, to Enter Hi-Tech Biosensor Market and Expand Its Diagnostic Product Portfolio XPhyto Announces Advertising Agreement with Agora Internet Relations Corp. XPhyto Supplies 10 Test Centers in Berlin with 25-minute COVID-19 PCR Test InvestorBrandNetwork (IBN) Announces Latest Episode of The Bell2Bell Podcast featuring Hugh Rogers, CEO of XPhyto Therapeutics Corp. XPhyto Therapeutics Corp. Featured in Syndicated Broadcast Covering Latest Progress Report on Mescaline Program for Psychedelic Therapies XPhyto Provides Progress Report on Mescaline Program for Psychedelic Therapies XPhyto Rapid Point-of-Care COVID-19 PCR Test Offered for Sale in Germany XPhyto Provides Update on Drug Formulation and Development Business XPhyto Establishes Proof of Concept Station for Point-of-Care 25-minute COVID-19 PCR Test in Germany XPhyto Pursues Market Access in Israel for its COVID-19 PCR Rapid Test XPhyto Signs German Distribution, Storage and Logistics Agreement for 25-Minute COVID-19 PCR Test XPhyto adds Top-Level Executive Talent to its Global Operations XPhyto Therapeutics Corp. Featured in Syndicated Broadcast Covering Recent European Approval of 25-Minute COVID-19 PCR Test XPhyto Announces Update on Oral Thin Film Drug Delivery Programs XPhyto to Present at Virtual Life Sciences Forum on September 17 XPhyto Provides Update on Covid-19 Rapid Test XPhyto Announces OTCQB Venture Market Listing XPhyto announces European Approval for 25 Minute COVID-19 PCR Test XPhyto Partner Receives ISO Certification for 25-Minute COVID-19 RT-PCR Test XPhyto Completes Corporate Rebranding and Launches New Website XPhyto Provides Updated Comments on Promotional and Marketing Activity XPhyto Places First Order for 25-Minute Covid-19 RT-PCR Tests XPhyto Builds Commercial Team to Launch 25-Minute Covid-19 RT-PCR Test XPhyto Reports Vektor Pharma GMBH Lawsuit XPhyto European CE-IVD Application for 25-Minute COVID-19 RT-PCR Test XPhyto Adds Mescaline Production to Psychedelic Medicine Programs XPhyto to Present at LD Micro Main Event XPhyto Therapeutics Announces Investment XPhyto Secures Exclusive Psychedelic Drug Development Agreement RE-TRANSMISSION: XPhyto Appoints European Healthcare Executive to Board of Directors XPhyto Appoints European Healthcare Executive to Board of Directors XPhyto Announces RT-PCR Test for Point-of-Care COVID-19 Detection XPhyto Announces Update on Contract Drug Delivery Programs Emerging Markets Report: A Psychedelic Story Emerging Markets Report: Rapid Results